挽救性HDR近距离放疗联合外照射治疗根治性前列腺切除术后孤立性前列腺床复发的II期研究
这项前瞻性I-II期研究纳入16例根治性前列腺切除术后PSMA PET/CT或mpMRI检测到的孤立性前列腺床复发患者,接受挽救性HDR近距离放疗(19 Gy/2次)后行全前列腺床及盆腔淋巴结外照射并联合6个月ADT。中位随访3.7年,15/16例(93.8%)维持生化控制,无局部失败,仅1例2级晚期泌尿毒性,无3级晚期毒性。
要点
- 挽救性HDR近距离放疗联合EBRT对PSMA检测的孤立性前列腺床复发可行,早期生化控制率达93.8%。
- 中位随访3.7年无局部失败,仅1例2级晚期泌尿毒性,无3级晚期毒性。
- 患者报告泌尿和肠道生活质量6个月时较基线仅有轻微、非显著变化。
核心结论
- 挽救性HDR近距离放疗联合EBRT治疗PSMA检测的孤立性前列腺床复发可行,早期生化控制优异,生活质量保留且毒性良好。
- 因入组缓慢,试验未完成目标样本量即关闭,结果需在更大规模多中心试验中验证。
研究设计与样本
- 前瞻性I-II期研究(NCT06982469),2020至2024年纳入16例根治性前列腺切除术后孤立性前列腺床复发患者。
- HDR近距离放疗19 Gy分2次处方至CTV并严格限制OAR,随后行全前列腺床及盆腔淋巴结EBRT联合6个月ADT。
- 毒性采用CTCAE v5.0评估,生活质量采用EORTC QLQ-PR25评估。
主要发现
- 挽救时中位PSA为0.36 ng/mL,HDR计划所有剂量学目标均达到。
- 中位随访3.7年(范围2.3-5.2年),15/16例(93.8%)维持生化控制,无局部失败。
- 1例记录到2级晚期泌尿毒性,无3级晚期毒性。
- 患者报告泌尿和肠道领域在6个月时较基线仅有轻微、非显著变化。
关键数值与推荐
- HDR近距离放疗剂量为19 Gy分2次处方至CTV,OAR限制严格。
- EBRT覆盖全前列腺床及盆腔淋巴结,联合6个月ADT。
- 毒性分级采用CTCAE v5.0,生活质量采用EORTC QLQ-PR25。
临床怎么用
- 对于PSMA PET/CT或mpMRI检测到的孤立性前列腺床复发且PSA较低者,可考虑挽救性HDR近距离放疗联合EBRT。
- 该联合方案早期生化控制率高且晚期毒性低,但需在更大规模多中心试验中进一步验证。
局限性
- 试验因入组缓慢未完成目标样本量即关闭。
- 样本量小(16例),随访时间有限,结果需更大规模多中心试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biochemical recurrence after radical prostatectomy is common, and conventional salvage external beam radiotherapy (EBRT) achieves suboptimal control with significant late morbidity. Advances in PSMA PET/CT and multiparametric MRI enable precise detection of isolated prostate bed relapse (IPBR) at low PSA values. High-dose-rate (HDR) brachytherapy offers focal dose escalation with steep gradients, potentially improving control while sparing organs at risk (OARs). METHODS: We conducted a prospective phase I-II study (NCT06982469) of combined salvage high-dose-rate (HDR) brachytherapy followed by external beam radiotherapy (EBRT) for patients with IPBR. HDR was delivered as 19 Gy in two fractions prescribed to the clinical target volume (CTV) with strict organ-at-risk (OAR) constraints. EBRT to the whole prostate bed and elective pelvic lymph nodes followed combined with 6-month ADT. Toxicity was assessed using CTCAE v5.0 and quality of life with EORTC QLQ-PR25. RESULTS: Sixteen patients were enrolled between 2020 and 2024. Median PSA at salvage was 0.36 ng/mL. After HDR planning, all dosimetric objectives were met. At a median follow-up of 3.7 years (range, 2.3 - 5.2), 15 out of 16 patients (93.8 %) remained biochemically controlled, with no local failures. Grade 2 late urinary toxicity was documented in one case and no grade 3 late toxicites occurred. Patient-reported urinary and bowel domains showed only minor, non-significant changes at 6 months from baseline. CONCLUSIONS: Combined salvage HDR brachytherapy followed by EBRT for PSMA-detected IPBR is feasible, achieves excellent early biochemical control, and preserves quality of life with favorable toxicity. The trial was closed without completing the target size due to slow accrual although these results warrant confirmation in larger multicenter trials.
引用
- Vallés LF, Echeveste M, Torres M, et al. Phase II study of salvage HDR brachytherapy combined with external beam radiotherapy for isolated prostate bed relapse after radical prostatectomy: preliminary clinical results. Radiother Oncol. 2025. PMID: 41110803. doi:10.1016/j.radonc.2025.111215
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。